Pacific Stock Based Compensation vs Other Non Cash Items Analysis
PACB Stock | USD 1.99 0.19 10.56% |
Pacific Biosciences financial indicator trend analysis is much more than just breaking down Pacific Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacific Biosciences is a good investment. Please check the relationship between Pacific Biosciences Stock Based Compensation and its Other Non Cash Items accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Stock Based Compensation vs Other Non Cash Items
Stock Based Compensation vs Other Non Cash Items Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacific Biosciences Stock Based Compensation account and Other Non Cash Items. At this time, the significance of the direction appears to have strong relationship.
The correlation between Pacific Biosciences' Stock Based Compensation and Other Non Cash Items is 0.73. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Other Non Cash Items in the same time period over historical financial statements of Pacific Biosciences of, assuming nothing else is changed. The correlation between historical values of Pacific Biosciences' Stock Based Compensation and Other Non Cash Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Pacific Biosciences of are associated (or correlated) with its Other Non Cash Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Non Cash Items has no effect on the direction of Stock Based Compensation i.e., Pacific Biosciences' Stock Based Compensation and Other Non Cash Items go up and down completely randomly.
Correlation Coefficient | 0.73 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Other Non Cash Items
Most indicators from Pacific Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacific Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. The current year's Selling General Administrative is expected to grow to about 203.9 M, whereas Tax Provision is forecasted to decline to (12.9 M).
2022 | 2023 | 2024 | 2025 (projected) | Gross Profit | 49.0M | 52.8M | 60.7M | 63.7M | Total Revenue | 128.3M | 200.5M | 230.6M | 242.1M |
Pacific Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Pacific Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pacific Biosciences fundamental ratios Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Common Stock Shares Outstanding | 175.0M | 204.1M | 224.6M | 253.6M | 291.7M | 306.3M | |
Total Assets | 414.0M | 2.0B | 1.8B | 1.7B | 2.0B | 2.1B | |
Short Long Term Debt Total | 42.0M | 953.7M | 957.4M | 933.9M | 1.1B | 1.1B | |
Other Current Liab | 17.5M | 40.4M | 201.2M | 53.5M | 61.6M | 64.7M | |
Total Current Liabilities | 36.5M | 83.3M | 76.9M | 95.0M | 109.3M | 114.7M | |
Total Stockholder Equity | 335.5M | 791.0M | 562.9M | 701.3M | 806.5M | 846.8M | |
Other Liab | 2.0M | 10.3M | 215.0M | 2.6M | 3.0M | 2.8M | |
Property Plant And Equipment Net | 54.9M | 79.1M | 81.3M | 69.0M | 79.4M | 83.3M | |
Current Deferred Revenue | 10.3M | 36.0M | 32.3M | 16.3M | 18.8M | 13.1M | |
Net Debt | (276.8M) | 493.0M | 632.3M | 754.0M | 867.1M | 910.5M | |
Retained Earnings | (1.0B) | (1.2B) | (1.5B) | (1.8B) | (1.7B) | (1.6B) | |
Accounts Payable | 3.6M | 11.0M | 12.0M | 15.1M | 17.3M | 18.2M | |
Cash | 318.8M | 460.7M | 325.1M | 179.9M | 206.9M | 137.4M | |
Non Current Assets Total | 59.2M | 901.2M | 912.1M | 1.0B | 1.2B | 1.2B | |
Non Currrent Assets Other | 879K | 1.2M | 10.5M | 3.7M | 4.3M | 3.7M | |
Other Assets | 33.5M | 1.2M | 13.5M | 1.0 | 1.15 | 1.09 | |
Cash And Short Term Investments | 318.8M | 1.0B | 772.3M | 631.4M | 726.1M | 762.4M | |
Short Term Investments | 237.2M | 583.7M | 447.2M | 451.5M | 519.2M | 545.2M | |
Liabilities And Stockholders Equity | 414.0M | 2.0B | 1.8B | 1.7B | 2.0B | 2.1B | |
Non Current Liabilities Total | 42.0M | 1.1B | 1.1B | 949.7M | 1.1B | 1.1B | |
Other Current Assets | 5.7M | 7.9M | 10.6M | 17.3M | 19.9M | 20.9M | |
Other Stockholder Equity | 1.4B | 2.0B | 2.1B | 2.5B | 2.9B | 3.1B | |
Total Liab | 78.5M | 1.2B | 1.2B | 1.0B | 1.2B | 1.3B | |
Property Plant And Equipment Gross | 54.9M | 79.1M | 81.3M | 143.8M | 165.4M | 173.7M | |
Total Current Assets | 354.8M | 1.1B | 855.0M | 742.0M | 853.4M | 896.0M | |
Accumulated Other Comprehensive Income | 85K | (1.1M) | (4.8M) | 219K | 197.1K | 207.0K | |
Short Term Debt | 8.7M | 9.3M | 19.6M | 10.1M | 11.6M | 8.2M | |
Property Plant Equipment | 30.1M | 24.9M | 79.1M | 81.3M | 93.5M | 98.2M | |
Net Receivables | 16.8M | 24.2M | 18.8M | 36.6M | 42.1M | 44.2M | |
Common Stock Total Equity | 150K | 153K | 192K | 221K | 198.9K | 189.0K | |
Inventory | 14.2M | 24.6M | 50.4M | 56.7M | 65.2M | 68.4M | |
Common Stock | 192K | 221K | 227K | 268K | 241.2K | 229.1K | |
Net Tangible Assets | 54.9M | 335.5M | (30.0M) | (257.3M) | (231.6M) | (220.0M) | |
Retained Earnings Total Equity | (982.1M) | (1.1B) | (1.0B) | (1.2B) | (1.1B) | (1.2B) | |
Non Current Liabilities Other | 40.0M | 178.9M | 180.6M | 20.3M | 23.3M | 22.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.BTC | Bitcoin | |
TRX | TRON | |
BNB | Binance Coin |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share | Quarterly Revenue Growth (0.28) | Return On Assets | Return On Equity |
The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.